US 12018260
Tunable Reversir™ compounds
granted A61KA61K31/702
Quick answer
US patent 12018260 (Tunable Reversir™ compounds) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/702